Skip to main content
. 2019 Oct 1;9(10):2120–2139.

Figure 10.

Figure 10

Role of MAPK in GSK343-induced SREBP2 activation. A. HepG2 and PLC5 cells were treated with 20 μM GSK343 for the indicated time intervals. The whole cell lysates were analyzed by western blotting. B. HepG2 and PLC5 cells were pretreated with 20 μM of PD98059, SB202190, or SP600125 for 1 h and then exposed to GSK343 for 6 h. The whole cell lysates were analyzed by western blotting. C. HepG2 and PLC5 cells were treated GSK343 with or without 10 μM of PD98059, SB202190, or SP600125 for 72 h. Cell viability was analyzed by MTS assay. D. HepG2 and PLC5 cells were treated with 20 μM GSK343 or 50 ng/mL anisomycin (Aniso) for 0.5 h. The whole cell lysates were analyzed by western blotting. E. HepG2 cells were treated with DMSO or 20 μM GSK343 for 2 h. The cell lysates were analyzed by in vitro p38 MAPK activity assay. Blank without the addition of cell lysates was performed as a negative control.